Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study
Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy
Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survival
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
